Neurological Sciences

, Volume 29, Supplement 1, pp 123–126

Central mechanism of action of antimigraine prophylactic drugs

  • Gerardo Casucci
  • Veronica Villani
  • Fabio Frediani
Current Reality in Headache Treatments

Abstract

The pathogenesis of migraine is obscure. A hyperexcitable brain state has been postulated. Cortical spreading depression (CSD) is the most suggestive argument for the brain hyperexcitability. It has been showed that valproate, topiramate, amitriptyline and propranolol inhibit CSD in rats, which suggests that most preventative treatments of migraine act by normalising neuronal firing and increasing a genetically lowered and environmentally modified threshold for neuronal discharge. It has also been suggested that some antimigraine prophylactic drugs (i.e., amitriptyline, candesartan and magnesium) may act by restoring central nociceptive dysmodulation.

Keywords

Migraine Cortical spreading depression Hyperexcitability Central action Prophylactic drugs 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Welch KM, D’Andrea G, Tepley N et al (1990) The concept of migraine as a state of central neuronal hyperexcitability. Neurol Clin 8:817–828PubMedGoogle Scholar
  2. 2.
    Van der Kamp W, Maassen VanDenBrink A, Ferrari MD, van Dijk JG (1996) Interictal cortical hyperexcitability in migraine patients demonstrated with transcranial magnetic stimulation. J Neurol Sci 139:106–110PubMedCrossRefGoogle Scholar
  3. 3.
    Aurora SK, Barrodale P, Chronicle EP, Mulleners WM (2005) Cortical inhibition is reduced in chronic and episodic migraine and demonstrates a spectrum of illness. Headache 45:546–552PubMedCrossRefGoogle Scholar
  4. 4.
    Ramadan NM, Buchanan TM (2006) New and future migraine therapy. Pharmacol Ther 112:199–212PubMedCrossRefGoogle Scholar
  5. 5.
    Bolay H, Reuter U, Dunn AK et al (2002) Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 8:136–142PubMedCrossRefGoogle Scholar
  6. 6.
    Haut SR, Bigal ME, Lipton RB (2006) Chronic disorders with episodic manifestations: focus on epilepsy and migraine. Lancet Neurol 5:148–157PubMedCrossRefGoogle Scholar
  7. 7.
    Piao ZG, Cho IH, Park CK et al (2006) Activation of glia and microglial p38 MAPK in medullary dorsal horn contributes to tactile hypersensitivity following trigeminal sensory nerve injury. Pain 121:219–231PubMedCrossRefGoogle Scholar
  8. 8.
    Burstein R, Cutrer MF, Yarnitsky D (2000) The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 123:1703–1709PubMedCrossRefGoogle Scholar
  9. 9.
    Welch KM, Nagesh V, Aurora SK, Gelman N (2001) Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache 41:629–637PubMedCrossRefGoogle Scholar
  10. 10.
    Ayata C, Jin H, Kudo C et al (2006) Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 59:652–661PubMedCrossRefGoogle Scholar
  11. 11.
    Goadsby PJ (1997) How do currently used prophylactic agents work in migraine? Cephalalgia 17:85–92PubMedCrossRefGoogle Scholar
  12. 12.
    Welch KM (2005) Brain hyperexcitability: the basis for antiepilectic drugs in migraine prevention. Headache 45[Suppl 1]:S25–S32PubMedCrossRefGoogle Scholar
  13. 13.
    Ramadan NM. (2007) Current trends in migraine prophylaxis. Headache 47[Suppl 1]:S52–S57PubMedCrossRefGoogle Scholar
  14. 14.
    Glauser TA (1999) Topiramate. Epilepsia 40[Suppl 5]:S71–S80PubMedCrossRefGoogle Scholar
  15. 15.
    Brandes JL, Saper JR, Diamond M et al; MIGR-002 Study Group (2004) Topiramate for migraine prevention: a randomized controlled trial. JAMA 291:965–973PubMedCrossRefGoogle Scholar
  16. 16.
    Silberstein SD (2004) Topiramate in migraine prevention: evidence-based medicine from clinical trials. Neurol Sci 25[Suppl 3]:S244–S245PubMedCrossRefGoogle Scholar
  17. 17.
    Bussone G, Diener HC, Pfeil J, Schwalen S (2005) Topiramate 100 mg/day in migraine prevention: a pooled analysis of doubleblind randomised controlled trials. Int J Clin Pract 59:961–968PubMedCrossRefGoogle Scholar
  18. 18.
    Diamond M, Dahlöf C, Papadopoulos G et al (2005) Topiramate improves health-related quality of life when used to prevent migraine. Headache 45:1023–1030PubMedCrossRefGoogle Scholar
  19. 19.
    Winner P, Gendolla A, Stayer C et al (2006) Topiramate for migraine prevention in adolescents: a pooled analysis of efficacy and safety. Headache 46:1503–1510PubMedCrossRefGoogle Scholar
  20. 20.
    Lakshmi CV, Singhi P, Malhi P, Ray M (2007) Topiramate in the prophylaxis of pediatric migraine: a double-blind placebo-controlled trial. J Child Neurol 22:829–835PubMedCrossRefGoogle Scholar
  21. 21.
    Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE (2000)An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 41[Suppl 1]:S3–S9PubMedCrossRefGoogle Scholar
  22. 22.
    Löscher W (1999) Valproate: a reappraisal of its pharmacodynamic properties and mechanism of action. Prog Neurobiol 58:31–59PubMedCrossRefGoogle Scholar
  23. 23.
    Hering R, Kuritzky A (1992) Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 12:81–84PubMedCrossRefGoogle Scholar
  24. 24.
    Jensen R, Brinck T, Olesen J (1994) Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology 44:647–651PubMedGoogle Scholar
  25. 25.
    Klapper J (1997) Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 17:103–108PubMedCrossRefGoogle Scholar
  26. 26.
    Freitag FG, Collins SD, Carlson HA et al; Depakote ER Migraine Study Group (2002) A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 58:1652–1659PubMedGoogle Scholar
  27. 27.
    Steiner TJ, Findley LJ, Yuen AW (1997) Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 17:109–112PubMedCrossRefGoogle Scholar
  28. 28.
    D’Andrea G, Granella F, Cadaldini M, Manzoni GC (1997) Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. Cephalalgia 19:64–66CrossRefGoogle Scholar
  29. 29.
    Lampl C, Katsarava Z, Diener HC, Limmroth V (2005) Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry 76:1730–1732PubMedCrossRefGoogle Scholar
  30. 30.
    Pascual J, Caminero AB, Mateos V et al (2004) Preventing disturbing migraine aura with lamotrigine: an open study. Headache 44:1024–1028PubMedCrossRefGoogle Scholar
  31. 31.
    Lang DG, Wang CM, Cooper BR (1993) Lamotrigine, phenytoin and carbamazepine interactions on the sodium current present in N4TG1 mouse neuroblastoma cells. J Pharmacol Exp Ther 266:829–835PubMedGoogle Scholar
  32. 32.
    Stefani A, Spadoni F, Siniscalchi A, Bernardi G (1996) Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications. Eur J Pharmacol 307:113–116PubMedCrossRefGoogle Scholar
  33. 33.
    Wang SJ, Tsai JJ, Gean PW (1998) Lamotrigine inhibits depolarization-evoked Ca influx in dissociated amygdale neurons. Synapse 29:355–362PubMedCrossRefGoogle Scholar
  34. 34.
    Buchanan TM, Ramadan NM. (2006) Prophylactic pharmacotherapy for migraine headaches. Semin Neurol 26:188–198PubMedCrossRefGoogle Scholar
  35. 35.
    Silberstein SD, Goadsby PJ (2002) Migraine preventative treatment. Cephalalgia 22:491–512PubMedCrossRefGoogle Scholar
  36. 36.
    Ablad B, Dahlöf C (1986) Migraine and beta-blockade: modulation of sympathetic neurotransmission. Cephalalgia 6[Suppl 5]:7–13PubMedGoogle Scholar
  37. 37.
    Koella WP (1985) CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action. Eur J Clin Pharmacol 28[Suppl]:55–63PubMedCrossRefGoogle Scholar
  38. 38.
    Ricther F, Mikulik O, Ebersberger A, Schaible HG (2005) Noradrenergic agonists and antagonists influence migration of cortical spreading depression in rat — a possible mechanism of migraine prophylaxis and prevention of postischemic neuronal damage. J Cerebr Blood Flow Metab 25:1225–1235CrossRefGoogle Scholar
  39. 39.
    Lewis D, Ashwal S, Hershey A et al American Academy of Neurology Quality Standards Subcommittee; Practice Committee of the Child Neurology Society (2004) Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology 63:2215–2224PubMedGoogle Scholar
  40. 40.
    Overweg J, Binnie CD, Meijer JW et al (1984) Double-blind placebo-controlled trial of flunarizine as add-on therapy in epilepsy. Epilepsia 25:217–222PubMedCrossRefGoogle Scholar
  41. 41.
    Starreveld E, de Beukelaar F, Wilson AF et al (1989) Double-blind cross-over placebo controlled study of flunarizine in patients with therapy resistant epilepsy. Can J Neurol Sci 16:187–190PubMedGoogle Scholar
  42. 42.
    Casucci G, Di Costanzo A, Riva R et al (1994) Central action of Cinnarizine and Flunarizine: a saccadic eye movement study. Clin Neuropharmacol 5:417–422CrossRefGoogle Scholar
  43. 43.
    Bellavance AJ, Meliche JP (1990) A comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis. Headache 30:710–715PubMedCrossRefGoogle Scholar
  44. 44.
    Lawrence ER, Hossain M, Littlestone W (1977) Sandomigran for migraine prophylaxis, controlled multicenter trial in general practice. Headache 17:109–112PubMedCrossRefGoogle Scholar
  45. 45.
    Mylecharane EJ (1991) 5-HT2 receptor antagonists and migraine therapy. J Neurol 238[Suppl 1]:S45–52PubMedCrossRefGoogle Scholar
  46. 46.
    Tronvik E, Stovner LJ, Helde G et al (2003) Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 289:65–69PubMedCrossRefGoogle Scholar
  47. 47.
    Bigal M, Bordini CA, Tepper SJ, Speciali JG (2002) Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Cephalalgia 22:345–353PubMedCrossRefGoogle Scholar
  48. 48.
    Ramadan NM, Silberstein SD, Freitag FG et al (2000). Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for the prevention of migraine. Available at http://www.aan.com/professionals/practice/pdfs/gl0090.pdf
  49. 49.
    Battistini S, Stenirri S, Piatti M et al (1999) A new CACNA1A gene mutation in acetazolamide-responsive familial hemiplegic migraine and ataxia. Neurology 53:38–43PubMedGoogle Scholar
  50. 50.
    Athwal BS, Lennox GG (1996) Acetazolamide responsiveness in familial hemiplegic migraine. Ann Neurol 40:820–821PubMedCrossRefGoogle Scholar
  51. 51.
    Shank RP, Doose DR, Streeter AJ, Bialer M (2005) Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase. Epilepsy Res 63:103–112PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2008

Authors and Affiliations

  • Gerardo Casucci
    • 1
  • Veronica Villani
    • 2
  • Fabio Frediani
    • 3
  1. 1.Casa di Cura S. FrancescoTelese Terme (BN)Italy
  2. 2.Neurology UnitS. Andrea Hospital “La Sapienza” UniversityRomeItaly
  3. 3.Neurological Department and Headache CenterPoliclinico “S. Pietro”Ponte San Pietro (BG)Italy

Personalised recommendations